Premium
What is the relationship between eye drops and women in science?
Author(s) -
Kolko Miriam
Publication year - 2019
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2019.8318
Subject(s) - optometry , glaucoma , ophthalmology , jungle , intraocular pressure , medicine , human eye , history , computer science , artificial intelligence , archaeology
Despite the multifactorial nature of glaucoma, it is evident that treatments to lower the intraocular pressure (IOP) decrease the rate of glaucomatous progression. Within the available treatments, IOP‐lowering eye drops are the far most common strategy. In 2011, the most prescribed anti‐glaucomatous eye drops, Xalatan, went out of patent and since then multiple generic eye drops has entered the market. Although it is an obvious benefit to eradicate the monopoly, the minimum requirements for the introduction of generic eye drops are worrying. Thus, increasing evidence have shown significant differences between generic anti‐glaucomatous eye drops and their brand name products. Moreover, differences in‐between the generic eye drops exist. To complicate it even more, generic Xalatan has changed and is now different from its original form. Overall, it is a jungle and only by improving research, education, and behaviour, the availability of the various treatment options will be rewarding. With a humorous, but serious, angle, the jungle of current available anti‐glaucomatous eye drops will be compared to the challenging career path of women in science.